High-dose chemotherapy and autologous peripheral blood stem cell transplantation in high-risk multiple myeloma

European Journal of Haematology

Volumn 73, Issue 3, 2004, Pages 169-173

  Murakami, Hirokazu ^a   Fujii, Hiroshi ^b   Inaba, Tohru ^c   Shimazaki, Chihiro ^c   Okamoto, Sinichirou ^d   Miwa, Akiyosi ^e   Sawamura, Morio ^f   Abe, Masahiro ^g   Chou, Takaaki ^h   Asaoku, Hideki ⁱ   Kitahara, Yoshikazu ^a   Hayashi, Kunihiko ^a   Kosaka, Masaaki ^j   Togawa, Atsushi ^k   Takatsuki, Kiyoshi ^l  

^a GUNMA UNIVERSITY   (Japan)

^b JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^d KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^f Shibukawa Medical Center   (Japan)

^g UNIVERSITY OF TOKUSHIMA   (Japan)

^h NIIGATA CANCER CENTER HOSPITAL   (Japan)

ⁱ ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

^j Tokushima Pref Hospital of Kaifu   (Japan)

^k National Hospital Organization Kofu National Hospital   (Japan)

^l Kitano Hospital   (Japan)

more..

Author keywords

Morphology; Myeloma; Prognostic factor; Stem cell transplantation; Stratification

Indexed keywords

BETA 2 MICROGLOBULIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; PREDNISOLONE; RANIMUSTINE; SERUM ALBUMIN; VINCRISTINE;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOTRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL STRUCTURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; MYELOMA CELL; PATIENT CODING; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; TREATMENT INDICATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA 2-MICROGLOBULIN; CELL SIZE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RISK FACTORS; SERUM ALBUMIN; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS;

EID: 4043090560     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2004.00282.x     Document Type: Article

References (20)

1. ALEXANIAN R. Treatment of multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 1969;208:1680-1685.
2. The Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients form 27 randomized trials. J Clin Oncol 1998;16:3832-3842.
3. ATTAL M, HARSOUSSEAU J-L, STOPPA A-M et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335:91-97.
4. BARLOGIE B, JAGANNTH S, DESIKAN KR et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999;93:55-65.
5. DURIE BGM, SALMON SE. A clinical staging system for multiple myeloma. Cancer 1975;36:842-854.
6. GREIPP PR, RAYMOND NM, KYLE RA, O'FALLON WM. Multiple myeloma: significance of plasmablastic subtype in morphological classification. Blood 1985;65:305-310.
7. MURAKAMI H, KAWADA T, SAITOH T et al. A staging system for multiple myeloma based on the morphology of myeloma cells. Eur J Hematol 1999;62:63-67.
8. CHILD JA, MORGAN GJ, DAVIES FE, OWEN RG, BELL SE, HAWKINS K, BROWN J, DRAYSON MT, SELBY PJ. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-1883.
9. Medical Research Council's Working Party on Leukemia in Adults. Prognostic features in the third MRC myelomatosis trial. Brit J Cancer 1980;42:831-840.
10. BATAILLE R, DURIE BGM, GRENIER J, SANY J. Prognostic factors and staging in multiple myeloma: a reappraisal. J Clin Oncol 1986;4:80-87.
11. GREIPP PR, KATZMANN JA, O'FALLON M, KYLE A. Value of β2- microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood 1988;72:219-223.
12. DURIE BGM, STOCK-NOVACK D, SALMON SE, FINLEY P, BECKORD J, CROWLEY J, COLTMAN CA. Prognostic value of pretreatment serum β2-microglobulin in myeloma: a Southwest Oncology Group Study. Blood 1990;75:823-830.
13. CIMINO G, AVVISATI G, AMADORI S et al. High serum IL-2 levels are predictive of prolonged survival in multiple myeloma. Brit J Haematol 1990;75:373-377.
14. DIMOPOULOS MA, BARLOGIE B, SMITH TL, ALEXANIAN R. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Int Med 1991;115:931-935.
15. BATAILLE R, BOCCADORO M, KLEIN B, PILERI A. C-reactive protein and β2-microglobulin produce a simple and powerful myeloma staging system. Blood 1992;80:733-737.
16. GREIPP PR, LUST JA, O'FALLON WM, KATMANN JA, WITZIG TE, KYLE RA. Plasma cell labeling index and β2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 1993;81:3382-3387.
17. MERLINI G, PERFETTI V, GOBBI PG, QUAGLINI S, FRANCIOTTA DM, MARINONE G, ASCARI E. Acute phase protein and prognosis in multiple myeloma. Brit J Haematol 1993;83:595-601.
18. SAN MIGUEL JF, GARCIA-SANZ R, GONZALEZ M et al. A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood 1995;85:448-455.
19. MURAKAMI H, NEMOTO K, SAWAMURA M et al. Prognostic relevance of morphological classification in multiple myeloma. Acta Haematol 1992;87:113-117.
20. FACON T, AVET-LOISEAU H, GUILLERM G et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta-2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001;97:1566-1571.